Navigation Links
Icahn School of Medicine at Mount Sinai awarded $2.7 million from NIH to investigate novel therapy for eczema
Date:11/25/2013

The National Institutes of Health has awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate to severe atopic dermatitis (AD), also known as eczema. Currently, no treatments are available that achieve long-term remission without difficult side effects for this debilitating skin disorder, characterized by inflammation, severe itching, and a rash that can adversely affect many aspects of everyday life.

The team will investigate the efficacy of a new intravenous medication, ILV-094, which blocks IL-22, an important protein that has been shown in animal models to trigger epidermal growth and differentiation abnormalities and chronic inflammation, which are major features of AD. The researchers see the study as potentially groundbreaking in using "narrow pathway"-targeted immune interventions for not just AD, but other "allergic" inflammatory diseases of the skin or other organs, such as asthma.

At the Icahn School of Medicine at Mount Sinai, Emma Guttman, MD, PhD, Associate Professor of Dermatology, and Director of the Laboratory for Inflammatory Skin Diseases, and Mark Lebwohl, MD, Professor and Chair of Dermatology, will lead the study. James G. Krueger, MD, PhD, D. Martin Carter Professor and head of the Laboratory for Investigative Dermatology at The Rockefeller University, will oversee the mechanistic studies for the trial. Dr. Guttman has a joint appointment at Rockefeller and will conduct clinical and mechanistic studies at both institutions.

Dr. Guttman was the first investigator to show in humans that a separate population of T cells secrete interleukin 22 (IL-22) and she also discovered the importance of the Th22 pathway and IL-22 in AD.

"Dr. Guttman has been at the forefront of many of the most important strides in understanding the pathophysiology of atopic dermatitis," said Dr. Lebwohl. "This trial is an important step in developing safer treatments for patients with moderate to severe AD."

"I hope that this research results in a final proof of concept and a novel treatment for AD without side effects," said Dr. Guttman. The clinical trial is expected to last five years. The majority of the clinical trial, will be conducted at the Icahn School of Medicine at Mount Sinai.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Icahn School of Medicine at Mount Sinai Honors Innovators in Scientific Research and Health Care Philanthropy at 2013 Commencement Ceremony
2. Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh to Collaborate on Clinical Studies for Mucopolysaccaridoses
3. Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration
4. Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles
5. World-Renowned Gastroenterologist Jean-Frédéric Colombel, MD, Joins the Icahn School of Medicine at Mount Sinai
6. Janina A. Longtine, MD of the Icahn School of Medicine at Mount Sinai Elected President of the Association for Molecular Pathology
7. A Best Manuscript Award Goes to the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai
8. A Best Manuscript Award goes to Icahn School of Medicine at Mount Sinai
9. Four Researchers from Icahn School of Medicine at Mount Sinai Among the 400 Most Highly Influential Biomedical Researchers in the World
10. Even Preschoolers View the Overweight Negatively
11. Catastrophic Head Injuries to High School Football Players Rising
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 ... of the "Structural Electronics 2015-2025: Applications, Technologies, ... In-Mold Electronics, Smart Skin, ... Photovoltaics Structural electronics involves electronic ... load-bearing, protective structures, replacing dumb structures such as ...
Breaking Medicine Technology: